Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

被引：0
|
作者：
Margaret P. Staples
Lyn March
Catherine Hill
Marissa Lassere
Rachelle Buchbinder
机构：
[1] Cabrini Institute,Monash Department of Clinical Epidemiology
[2] Monash University,Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine
[3] Royal North Shore Hospital,Florance and Cope Professorial Department of Rheumatology
[4] Institute of Bone and Joint Research,Discipline of Medicine
[5] University of Sydney,undefined
[6] The Queen Elizabeth and Royal Adelaide Hospitals,undefined
[7] University of Adelaide,undefined
[8] St George Hospital,undefined
[9] University of New South Wales,undefined
来源：
BMC Rheumatology | / 3卷
关键词：
Rheumatoid arthritis; Malignancy; Tumour necrosis factor; Biologic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 44 条
  • [41] Presence of Peripheral Arthritis and Male Sex Predicting Continuation of Anti-Tumor Necrosis Factor Therapy in Ankylosing Spondylitis: An Observational Prospective Cohort Study From the South Swedish Arthritis Treatment Group Register
    Kristensen, L. E.
    Karlsson, J. A.
    Englund, M.
    Petersson, I. F.
    Saxne, T.
    Geborek, P.
    ARTHRITIS CARE & RESEARCH, 2010, 62 (10) : 1362 - 1369
  • [42] Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
    Bluett, J.
    Ibrahim, I.
    Plant, D.
    Hyrich, K. L.
    Morgan, A. W.
    Wilson, A. G.
    Isaacs, J. D.
    Barton, A.
    PHARMACOGENOMICS JOURNAL, 2014, 14 (02) : 171 - 175
  • [43] Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
    J Bluett
    I Ibrahim
    D Plant
    K L Hyrich
    A W Morgan
    A G Wilson
    J D Isaacs
    A Barton
    The Pharmacogenomics Journal, 2014, 14 : 171 - 175
  • [44] Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year
    Sano, Hiroshige
    Arai, Katsumitsu
    Murai, Takehiro
    Fujisawa, Junichi
    Kondo, Naoki
    Netsu, Takahiro
    Hanyu, Tadamasa
    Saeki, Takako
    Ito, Tomoyuki
    Endo, Naoto
    MODERN RHEUMATOLOGY, 2009, 19 (04) : 390 - 394
12345